230 related articles for article (PubMed ID: 8462316)
1. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel.
Davies GC; Feng LX; Newton JR; Van Beek A; Coelingh-Bennink HJ
Contraception; 1993 Mar; 47(3):251-61. PubMed ID: 8462316
[TBL] [Abstract][Full Text] [Related]
2. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
[TBL] [Abstract][Full Text] [Related]
3. Temporal relationship between Uniplant insertion and changes in cervical mucus.
Barbosa IC; Coutinho E; Hirsch C; Ladipo OA; Olsson SE; Ulmsten U
Contraception; 1996 Oct; 54(4):213-7. PubMed ID: 8922874
[TBL] [Abstract][Full Text] [Related]
4. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
5. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant.
Mäkäräinen L; van Beek A; Tuomivaara L; Asplund B; Coelingh Bennink H
Fertil Steril; 1998 Apr; 69(4):714-21. PubMed ID: 9548163
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
7. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
8. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days.
Csemiczky G; Dieben T; Coeling Bennink HJ; Landgren BM
Contraception; 1996 Dec; 54(6):333-8. PubMed ID: 8968661
[TBL] [Abstract][Full Text] [Related]
9. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol.
Wenzl R; Bennink HC; van Beek A; Spona J; Huber J
Fertil Steril; 1993 Oct; 60(4):616-9. PubMed ID: 8405513
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
Jung-Hoffmann C; Fitzner M; Kuhl H
Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon®.
Weisberg E; Croxatto HB; Findlay JK; Burger HG; Fraser IS
Contraception; 2011 Dec; 84(6):600-8. PubMed ID: 22078189
[TBL] [Abstract][Full Text] [Related]
12. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
[TBL] [Abstract][Full Text] [Related]
13. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant.
Zheng SR; Zheng HM; Qian SZ; Sang GW; Kaper RF
Contraception; 1999 Jul; 60(1):1-8. PubMed ID: 10549446
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel.
Jackson R; Newton JR
Contraception; 1989 Jun; 39(6):653-64. PubMed ID: 2752753
[TBL] [Abstract][Full Text] [Related]
15. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
16. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
17. Subdermal contraceptive implants.
Peralta O; Diaz S; Croxatto H
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
[TBL] [Abstract][Full Text] [Related]
18. Clinical results with subcutaneous implants containing 3-keto desogestrel.
Olsson SE; Odlind V; Johansson E
Contraception; 1990 Jul; 42(1):1-11. PubMed ID: 2117514
[TBL] [Abstract][Full Text] [Related]
19. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
